Prostate-specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer but it possesses serious limitations.
Therefore, there is an urgent need for more sensitive and specific biomarkers for prostate cancer prognosis and patient follow-up. Recent advances led to the discovery of many novel diagnostic/prognostic techniques and provided us with many worthwhile candidates. This paper briefly reviews the most promising biomarkers with respect to their implementation in screening, early detection, diagnostic confirmation, prognosis, and prediction of therapeutic response or monitoring disease and recurrence; and their use as possible therapeutic targets. This review also examines the possible future directions in the field of prostate cancer marker research.
Written by:
Dimakakos A, Armakolas A, Koutsilieris M. Are you the author?
Physiology Laboratory, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 11527 Athens, Greece.
Reference: Biomed Res Int. 2014;2014:890697.
doi: 10.1155/2014/890697
PubMed Abstract
PMID: 24877145
UroToday.com Prostate Cancer Section
